Alex Weniger-Araujo is a transactional partner whose practice is focused on corporate finance, venture finance, corporate governance, and general corporate law matters. He represents both foreign and domestic, emerging growth and high-technology issuers and investors in equity crowdfunding, public and private offerings and mergers and acquisitions transactions, including SPAC IPOs, business combinations (de-SPAC) and PIPE financing transactions, and advises clients on public reporting requirements for issuers and shareholders.
Alex brings a distinctive background to his securities practice. Before entering private practice, he led product development for a legal technology company, founded a real estate analytics SaaS platform, and served as general counsel at a New York-based venture development firm focused on Seed to Series-A stage companies. That entrepreneurial experience informs his counsel to growth-stage companies and the sponsors and investors that work alongside them.
- Representation of a special purpose acquisition company in its business combination with a leading battery materials supplier.*
- Representation of a special purpose acquisition corporation in the completion of its $400 million business combination with a brand management partners of international beauty and personal care brands in China.*
- Representation of a publicly traded special purpose acquisition company in entering a definitive agreement and plan of merger for a business combination with a digital applications holdings company to create a public company with an enterprise value of $1.1 billion.*
- Representation of a special purpose acquisition company in its $123.5 million initial public offering.*
- Representation of a special purpose acquisition company in its $115 million initial public offering.*
- Representation of a special purpose acquisition company in its initial business combination with a clinical-stage biopharmaceutical company focused on the development or commercialization of innate immune system therapeutics and diagnostics.*
- Representation of a special purpose acquisition company in its $100 million SPAC offering.*
- Representation of a special purpose acquisition company in a $150 million SPAC offering. The over-allotment option was exercised in part for the sale of an additional 1,500,000 Units at a price of $10.00 per Unit resulting in total gross proceeds of $165.5 million.*
- Representation of a special purpose acquisition company in a $250 million SPAC offering. The over-allotment option was exercised in full for the sale of an additional 3,750,000 Units at a price of $10.00 per Unit resulting in total gross proceeds of $287.5 million.*
- Representation of a special purpose acquisition company in a $69 million SPAC offering.*
- Representation of a special purpose acquisition company in a $115 million SPAC offering.*
- Representation of a special purpose acquisition company, as issuer, in IPO of 5,000,000 units each consisting of one share of common stock and one redeemable warrant. The Units were sold at a price of $10.00 per Unit, generating aggregate gross proceeds to the Registrant of $50,000,000. The over-allotment option was exercised in part for the sale of an additional 733,920 Units at a price of $10.00 per Unit resulting in additional total gross proceeds of $7,339,200.*
- Representation of a business staffing firm in the filing of initial public offerings for four special purpose acquisition companies that would raise $1.25 billion combined.*
- Representation of a special purpose acquisition company in its initial business combination with a private precision oncology company developing novel therapeutics for the treatment of cancer.*
*A number of the above matters were handled prior to joining McGuireWoods LLP.